• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
ProteaseTag® Active Neutrophil Elastase Immunoassay used to predict future risk of exacerbation in bronchiectasis
Share
Neutrophil Elastase Immunoassay, News, ProteaseTag®

ProteaseTag® Active Neutrophil Elastase Immunoassay used to predict future risk of exacerbation in bronchiectasis

December 23, 2016
-
Posted by Webmaster

In a significant new study, a team at the University of Dundee has shown for the first time that sputum neutrophil elastase (NE) activity, when measured using the ProteaseTag® Active NE Immunoassay,  is a biomarker of disease severity and future risk of exacerbation in adults with bronchiectasis.  The full text of the University of Dundee press release is below.

PRESS RELEASE FROM THE UNIVERSITY OF DUNDEE

Researchers find predictor for chest infections in patients with common lung condition

A study conducted by the University of Dundee has shown for the first time that a simple test can predict chest infections before they happen in patients with bronchiectasis, a common lung condition which affects people of all ages and leads to thousands of hospital admissions every year in the UK.

Bronchiectasis is a long-term chronic condition where the airways of the lungs become abnormally widened, leading to a build-up of excess mucus that can make the lungs more vulnerable to infection. Patients can suffer from a persistent cough and breathlessness as well as persistent chest infections.

The condition is one that cannot be cured but the symptoms can be managed to increase the life quality of sufferers.

“The value of finding a test to predict infections before they happen is that we can make sure patients are given preventative medicines to keep them healthier and maintain a better quality of life,” said Dr James Chalmers, Senior Clinical Lecturer and Honorary Consultant Respiratory Physician at the University of Dundee.

Dr Chalmers led the new study, which enrolled more than 380 patients with bronchiectasis. The test measures an enzyme in the lungs that is released when infection is building up, but before patients necessarily have the symptoms of an infection. Patients testing positive for the enzyme, called neutrophil elastase, were more likely to have chest infections, and also experienced a more rapid deterioration in their condition over the course of 3 years.

The researchers utilised the ProteaseTag® Active NE Immunoassay, developed by ProAxsis Limited, a medical diagnostics company based in Belfast, to assess neutrophil elastase activity.

Dr James Chalmers said, “Bronchiectasis affects 1 in every 1000 adults in the UK, but doesn’t always receive the same attention as some other respiratory diseases, despite the devastating effects it has on many sufferers. There are no widely accepted biomarkers of disease progression in bronchiectasis, but our study has shown that measuring levels of the active form of neutrophil elastase provides a viable and exciting option for assessing and monitoring this disease.

“Bronchiectasis patients can suffer repeated chest infections, which means they can be taking multiple courses of antibiotics. In the era of antibiotic resistance, anything that can help reduce the number of courses of antibiotics would be a significant boost to patients and the community as a whole.

“We hope to do further trials next year with the aim of using this test to improve patient outcomes.”

Tayside is one the leading centres in Europe for research in bronchiectasis, with Dr Chalmers and colleagues caring for more than 600 patients across the region and leading a network of specialist centres across Europe for this condition. (www.bronchiectasis.eu)

Commenting on the study results, Dr David Ribeiro, CEO of ProAxsis, said, “We’re very excited by the outcome of this study. The authors have demonstrated that active neutrophil elastase, when measured using our ProteaseTag® technology, can support clinicians in predicting which bronchiectasis patients are most at risk of future exacerbations and worsening of their disease.”

The study was a collaboration between scientists at the University of Dundee, including Dr James Chalmers, Dr Jeffrey Huang and Dr Tom Fardon, and scientists from Belfast and Barcelona.

The study is published in the online version of the American Journal of Respiratory and Critical Care Medicine in December, and can be found on the American Thoracic Society website.

The full article can be viewed here: http://www.atsjournals.org/doi/abs/10.1164/rccm.201605-1027OC?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed&
or download the (142 pages / 2.2 Mb) pdf : Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis

 

NOTES TO EDITORS

The University of Dundee is one of the world’s top 200 universities and in 2016 was named Scottish University of the Year for the second consecutive year (Sunday Times Good University Guide).

Dundee is internationally recognised for the quality of its teaching and research and has a core mission to transform lives across society. We are the top ranked university in the UK for biological sciences research, according to the most recent Research Excellence Framework, the major survey of research quality.

See www.dundee.ac.uk for further details.

About ProAxsis Limited

ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of diseases. This test measures Neutrophil Elastase, a leading indicator of infection in patients with Cystic Fibrosis (CF), Chronic Obstructive Pulmonary Disease (COPD) and bronchiectasis, and an important drug target. The rapid and easy-to-use tests incorporate patented ProteaseTags®; smart molecules which trap an active protease within a complex biological sample and enable a visual readout of its presence. ProteaseTags® provide a unique tool to identify and quantify active protease biomarkers and will assist in the clinical validation of new therapeutics.

ProAxsis is part of the NetScientific Group and is one of the Group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queen’s University Belfast.

December 23, 2016

Related News

Other posts that you should not miss.
Conferences, News, ProteaseTag®

ProAxsis to present at 2016 North American Cystic Fibrosis Conference

October 26, 2016
-
Posted by Webmaster

ProAxsis will this week be presenting new data on its ProteaseTag® technology, at the North American Cystic Fibrosis Conference …

Read More
October 26, 2016
Posted by Webmaster
Conferences, News

ProAxsis CEO to present at Anglonordic Conference

May 30, 2017
-
Posted by Webmaster

Dr David Ribeiro, CEO of ProAxsis, will be attending the Anglonordic Life Sciences Conference, taking place in London …

Read More
May 30, 2017
Posted by Webmaster
News, ProteaseTag®

ProAxsis abstracts at 2017 American Thoracic Society Conference

May 5, 2017
-
Posted by Webmaster

ProAxsis will be presenting further data on its ProteaseTag® technology, at the American Thoracic Society Conference, which takes …

Read More
May 5, 2017
Posted by Webmaster
← PREVIOUS POST
ProAxsis gains backing of Innovate UK
NEXT POST →
ProAxsis’ ProteaseTag® NE Immunoassay highlighted at BTS 2016
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis Limited appoints first distributor for DACH region
    December 14, 2020

    ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active …

  • ProAxsis Limited supported by Innovate UK to accelerate work on inflammatory biomarkers associated with COVID-19
    December 10, 2020

    ProAxsis (www.proaxsis.com), the Belfast-based respiratory diagnostics company, today announces that it has been …

  • ProAxsis Limited recognised as Gold Level Innovator by Innovate NI
    December 2, 2020

    ProAxsis (www.proaxsis.com), the Belfast-based protease diagnostics company, is delighted to announce that it …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • February 21, 2021
    ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
  • December 14, 2020
    ProAxsis Limited appoints first distributor for DACH region
  • December 10, 2020
    ProAxsis Limited supported by Innovate UK to accelerate work on inflammatory biomarkers associated with COVID-19
LATEST TWEETS
Twitter
ProAxsis
Follow Me
ProAxsis is delighted to have received this support from Innovate UK - https://t.co/toTxOz9KK6
87 days ago
- ProAxsis
RT @GRobinsonDUP: I’m delighted that @ProAxsis based in East Belfast have been successful in their application for an Innovate UK Grant, wh…
87 days ago
- ProAxsis
We are delighted to announce that as of today, we have appointed an exclusive distributor for our portfolio of prod… https://t.co/rmCmIugsLa
108 days ago
- ProAxsis
Due to our continued expansion, we wish to recruit an Administration Officer. This post can be full-time or part-ti… https://t.co/k3wKwVfOKy
128 days ago
- ProAxsis
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProteaseTag® Active Neutrophil Elastase Immunoassay used to predict future risk of exacerbation in bronchiectasis | ProAxsis